Why has NICE said this?
Bortezomib was recommended because it is an effective treatment for people with multiple myeloma before having chemotherapy and stem cell transplantation, and its cost is justified by its benefits.
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.